QSAM Biosciences (OTCPK:QSAM) - Stock Price, News & Analysis

QSAM Stock Overview

QSAM Biosciences, Inc. se dedica al desarrollo de diversos medicamentos nucleares para el tratamiento del cáncer y enfermedades afines.

About the company

QSAM fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Risk Analysis

Los accionistas han sido diluidos sustancialmente en el último año

Los beneficios han disminuido en 32.4% al año en los últimos 5 años.

Tiene unos ingresos inferiores a 1 millón de dólares ($0)

Tiene menos de 1 año de cash runway

+ 2 more risks

QSAM Biosciences, Inc. Competitors

Neoleukin Therapeutics

NasdaqCM:NLTX

US$32.8m

LianBio

OTCPK:LIAN.Y

US$33.6m

Harvard Apparatus Regenerative Technology

OTCPK:HRGN

US$40.4m

Aprea Therapeutics

NasdaqCM:APRE

US$33.7m

Price History & Performance

Summary of all time highs, changes and price drops for QSAM Biosciences
Historical stock prices
Current Share Price	US$7.40
52 Week High	US$7.74
52 Week Low	US$3.73
Beta	1.81
1 Month Change	8.03%
3 Month Change	17.27%
1 Year Change	85.00%
3 Year Change	-71.97%
5 Year Change	-46.76%
Change since IPO	-98.55%

Recent updates

Shareholder Returns

	QSAM	US Biotechs	US Market
7D	0%	-1.7%	0.3%
1Y	85.0%	4.7%	26.2%

Rentabilidad frente al sector: QSAM superó al sector US Biotechs , que obtuvo un rendimiento del 7.1% el año pasado.

Rentabilidad vs. Mercado: QSAM superó al mercado US, que obtuvo un rendimiento del 18% el año pasado.

Price Volatility

Is QSAM's price volatile compared to industry and market?
QSAM volatility
QSAM Average Weekly Movement	12.1%
Biotechs Industry Average Movement	11.8%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.8%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: QSAMha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: QSAM(13%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de los valores de US.

About the Company

Founded	Employees	CEO	Website
2004	5	Doug Baum	https://qsambio.com

QSAM Biosciences, Inc. se dedica al desarrollo de diversos medicamentos nucleares para el tratamiento del cáncer y enfermedades relacionadas. La empresa participa en el desarrollo de CycloSam (Samaium-153 DOTMP), un radiofármaco dirigido a los huesos en fase clínica. Tiene un acuerdo de licencia con IGL Pharma, Inc. La empresa se conocía anteriormente como Q2Earth, Inc. y cambió su nombre a QSAM Biosciences, Inc. en septiembre de 2020.

QSAM Biosciences, Inc. Fundamentals Summary

How do QSAM Biosciences's earnings and revenue compare to its market cap?
QSAM fundamental statistics
Market cap	US$32.90m
Earnings (TTM)	-US$5.16m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-6.4x

P/E Ratio

Is QSAM overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
QSAM income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$5.16m
Earnings	-US$5.16m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-1.16
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	1.1%

How did QSAM perform over the long term?

See historical performance and comparison

QSAM Stock Overview

Rewards

Risk Analysis

QSAM Biosciences, Inc. Competitors

NasdaqCM:NLTX

US$32.8m

OTCPK:LIAN.Y

US$33.6m

OTCPK:HRGN

US$40.4m

NasdaqCM:APRE

US$33.7m

Price History & Performance

Recent News & Updates

Telix Pharmaceuticals Limited (ASX:TLX) signed a non-binding term sheet to acquire QSAM Biosciences, Inc. (OTCPK:QSAM) for $33.1 million.

Telix Pharmaceuticals Limited (ASX:TLX) signed a non-binding term sheet to acquire QSAM Biosciences, Inc. (OTCPK:QSAM) for $33.1 million.

QSAM Biosciences, Inc. announced that it has received $0.600001 million in funding

QSAM Biosciences, Inc. Adds the Nuclear Reactor at the University of Texas at Austin to its Radioisotope Production Supply Chain for its Bone Cancer Treatment Drug Candidate, CycloSam®

QSAM Biosciences Expands Its Study of Cyclosam(R) in the Treatment of Bone Cancer; Opens Patient Enrollment At Key Chicago Center, Insight Hospital and Medical Center

QSAM Biosciences, Inc. Receives Third U.S. Patent for Clinical-Stage Radiopharmaceutical Drug Candidate CycloSam

Recent updates

Telix Pharmaceuticals Limited (ASX:TLX) signed a non-binding term sheet to acquire QSAM Biosciences, Inc. (OTCPK:QSAM) for $33.1 million.

Telix Pharmaceuticals Limited (ASX:TLX) signed a non-binding term sheet to acquire QSAM Biosciences, Inc. (OTCPK:QSAM) for $33.1 million.

QSAM Biosciences, Inc. announced that it has received $0.600001 million in funding

QSAM Biosciences, Inc. Adds the Nuclear Reactor at the University of Texas at Austin to its Radioisotope Production Supply Chain for its Bone Cancer Treatment Drug Candidate, CycloSam®

QSAM Biosciences Expands Its Study of Cyclosam(R) in the Treatment of Bone Cancer; Opens Patient Enrollment At Key Chicago Center, Insight Hospital and Medical Center

QSAM Biosciences, Inc. Receives Third U.S. Patent for Clinical-Stage Radiopharmaceutical Drug Candidate CycloSam

QSAM Biosciences Inc. Receives Japanese Patent for Its Clinical Stage Radiopharmaceutical Drug Candidate, Cyclosam

QSAM Biosciences, Inc. Appoints Adam King as Chief Financial Officer of the Company

Qsam Biosciences Inc. Receives Rare Pediatric Disease Designation from FDA for Cyclosam in the Treatment of Osteosarcoma

QSAM Biosciences, Inc. Activates Clinical Sites and Opens Enrollment for its Phase 1 Clinical Trial of CycloSam® for the Treatment of Bone Cancer

QSAM Biosciences Announces FDA Clearance of IND for Samarium-153 DOTMP, an Investigational Radiopharmaceutical for the Treatment of Bone Cancer

QSAM Biosciences, Inc. announced delayed 10-Q filing

QSAM Biosciences, Inc. announced delayed 10-Q filing

QSAM Biosciences Announces Submission of IND Application for CycloSam® with FDA

QSAM Biosciences, Inc. announced delayed annual 10-K filing

QSAM Biosciences, Inc. Appoints Charles J. Link, Jr., M.D. to Board of Directors

QSAM Biosciences, Inc. announced that it has received $2.5 million in funding from Checkmate Capital Group LLC

QSAM Biosciences, Inc. Receives Favorable Safety Results in Study for Its Leading Radiopharmaceutical Drug Candidate

QSAM Biosciences, Inc. Announces the Resignation of Tristan Peitz as Director

QSAM Biosciences, Inc. announced delayed 10-Q filing

QSAM Biosciences, Inc. Announces Executive Changes

Shareholder Returns

Price Volatility

About the Company

QSAM Biosciences, Inc. Fundamentals Summary

0.0x

-6.4x

Earnings & Revenue